Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
about
Adjuvants: Classification, Modus Operandi, and LicensingAntibody-based immunotherapy of solid cancers: progress and possibilitiesCancer vaccinesTLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking.TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progressionCombined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Vaccine adjuvant uses of poly-IC and derivatives.Novel targets for natural killer/T-cell lymphoma immunotherapy.Using natural products to promote caspase-8-dependent cancer cell death.Mechanisms regulating immune surveillance of cellular stress in cancer.IL-1βR-dependent priming of antitumor CD4(+) T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect.Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response.Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
P2860
Q26747586-63746CD6-F119-4D5F-B242-2A0F8A50F23FQ26796542-4B6CF1BD-402B-42B1-838C-FD5C60A14F0EQ27024438-9C3A8F65-F714-47B4-8EDF-AF29A8CFAC59Q36212034-0E20C958-6416-4377-ABB1-5117E4623D3DQ36413746-8DBA8B62-5F8A-49D1-8889-403B7968FB22Q36801213-129E1D68-8030-487F-906A-B14CAFF6F2BFQ38259510-7912F058-080E-4B8E-8D8A-64E6B4AECC14Q38661106-03297324-1534-4D97-835F-95554A17E8DAQ38861356-7D89A065-2B09-4D3F-BC5D-607D22222EE3Q39458697-3D24365B-E9F6-42F2-BC92-60A19E6EBB38Q40449413-B529724E-B58E-4768-B6FB-FCFE99FC556FQ40517920-CA80E2D4-369E-478F-9A72-5BA22FE6FB37Q40877648-426D3EB9-7842-4C16-B567-7816E88A1BEAQ41421852-C2C42101-60F0-4749-9D03-BBBCE22FF01EQ47162004-447C0EB5-4699-4041-ABF5-2C28E9E2FBC0Q47369374-1D9B1675-FFA6-4B09-8A9F-3712747A4F96Q48505173-52023934-5D5E-4C20-BD81-D5C93650FBDDQ49787906-2AD904F9-434C-4A24-8DA6-41EC21076AFBQ50423292-45AE32C3-B768-448F-9A22-10FDB133A692Q52684506-33F9C216-4A91-4A01-A1D1-192E6C19E0F0Q54976860-588B4758-13EB-43F6-B268-E22E1C51C9DB
P2860
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combinatorial immunotherapy of ...... es against established tumors.
@en
Combinatorial immunotherapy of ...... es against established tumors.
@nl
type
label
Combinatorial immunotherapy of ...... es against established tumors.
@en
Combinatorial immunotherapy of ...... es against established tumors.
@nl
prefLabel
Combinatorial immunotherapy of ...... es against established tumors.
@en
Combinatorial immunotherapy of ...... es against established tumors.
@nl
P2093
P2860
P1476
Combinatorial immunotherapy of ...... es against established tumors.
@en
P2093
Esteban Celis
Toshihiro Nagato
Yasuaki Harabuchi
Young-Ran Lee
P2860
P304
P356
10.1158/1078-0432.CCR-13-2781
P407
P577
2014-01-03T00:00:00Z